Novan Inc Revenue Growth Rates (NOVN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Novan Inc   (NASDAQ: NOVN)
 

NOVN's Revenue Growth by Quarter and Year

Novan Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NOVN Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 3.17
FY 3.17

NOVNs Annual Revenue
Novan Inc 's Revenue in the fiscal year 2022 $ 23.68 millions
Novan Inc 's Revenue in the fiscal year 2021 $ 2.96 millions
Novan Inc 's Revenue in the fiscal year 2020 $ 4.92 millions
Novan Inc 's Revenue in the fiscal year 2019 $ 4.90 millions
Novan Inc 's Revenue in the fiscal year 2018 $ 5.99 millions




NOVN Revenue first quarter 2023 Y/Y Growth Comment
Novan Inc reported Revenue surge of 64.04% year on year in the first quarter 2023, to $ 3.17 millions, this is lower than Novan Inc 's recent average Revenue surge of 196.8%.

Looking into first quarter 2023 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Novan Inc ' s Revenue jump of 64.04% ranks overall at the positon no. 446 in the first quarter 2023.


NOVN Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 1487.88 % -38.32 % -22.46 %
3rd Quarter September - 591.89 % -43.94 % 0 %
2nd Quarter June - 721.33 % -43.18 % 20 %
1st Quarter March 64.04 % 135.37 % -32.23 % 10 %
FY   - 697.64 % -39.63 % -

Financial Statements
Novan Inc 's first quarter 2023 Revenue $ 3.17 millions NOVN's Income Statement
Novan Inc 's first quarter 2022 Revenue $ 1.93 millions Quarterly NOVN's Income Statement


NOVN Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 104.69 % -10.81 % -18.94 %
3rd Quarter September - -16.88 % -1.33 % 0 %
2nd Quarter June - 219.17 % -8.54 % 9.09 %
1st Quarter March -69.79 % 192.42 % -23.36 % -12.32 %
FY (Year on Year)   - 697.64 % -39.63 % -


Back to NOVN Growth rate Comparisons >> Back to NOVN Growth rate Comparisons >>


Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #121
Overall #446

Revenue Y/Y Growth Statistics
High Average Low
1500.15 % 196.8 % -65.83 %
(Dec 31 2022)   (Dec 31 2019)
Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #121
Overall #446
Revenue Y/Y Growth Statistics
High Average Low
1500.15 % 196.8 % -65.83 %
(Dec 31 2022)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Novan Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
569 % 58.66 % -72.75 %
(Jun 30 2017)  


NOVN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Novan Inc disclosed fall in Revenue from the fourth quarter by -69.79% to $ 3.17 millions, from $ 10.48 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 252 other companies have achieved higher Revenue quarter on quarter growth. While Novan Inc 's Revenue growth quarter on quarter, overall rank is 4111.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #253
Healthcare Sector #642
Overall #4111
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #253
Healthcare Sector #642
Overall #4111
Revenue Q/Q Growth Statistics
High Average Low
569 % 58.66 % -72.75 %
(Jun 30 2017)  


NOVN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Novan Inc disclosed fall in Revenue from the fourth quarter by -69.79% to $ 3.17 millions, from $ 10.48 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 252 other companies have achieved higher Revenue quarter on quarter growth. While Novan Inc 's Revenue growth quarter on quarter, overall rank is 4111.


Novan Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 24.92 $ 23.68 $ 13.86 $ 9.48 $ 4.07
Y / Y Revenue Growth (TTM) 512.74 % 700.61 % 310.91 % 139.83 % -10.14 %
Year on Year Revenue Growth Overall Ranking # 3169 # 3083 # 81 # 213 # 2798
Seqeuential Revenue Change (TTM) 5.23 % 70.92 % 46.19 % 133.05 % 37.49 %
Seq. Revenue Growth (TTM) Overall Ranking # 663 # 2825 # 97 # 49 # 141


Cumulative Revenue growth Comment
Assuming the Novan Inc 's fiscal year would have ended in Mar 31 2023, Novan Inc would have reprted above average annual Revenue surge of 512.74% year on year, of $ 25 millions.
This marks a slow-down of the companys growth trends and from the 700.61% surge in Dec 31 2022.

In the Healthcare sector 446 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3083 to 3169.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 65
Healthcare Sector # 447
Overall # 3169

Revenue TTM Y/Y Growth Statistics
High Average Low
700.61 %
 117.69 %
-39.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 65
Sector # 145
S&P 500 # 663
Cumulative Revenue growth Comment
Assuming the Novan Inc 's fiscal year would have ended in Mar 31 2023, Novan Inc would have reprted above average annual Revenue surge of 512.74% year on year, of $ 25 millions.
This marks a slow-down of the companys growth trends and from the 700.61% surge in Dec 31 2022.

In the Healthcare sector 446 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3083 to 3169.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 65
Healthcare Sector # 447
Overall # 3169

Revenue TTM Y/Y Growth Statistics
High Average Low
700.61 %
117.69 %
-39.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 65
Sector # 145
S&P 500 # 663




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NOVN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Rayont Inc 110.98%$ 110.979 millions
Emmaus Life Sciences Inc 108.81%$ 108.813 millions
Sage Therapeutics Inc 108.22%$ 108.217 millions
Serina Therapeutics Inc 100.00%$ 100.000 millions
Sanara Medtech Inc 98.71%$ 98.713 millions
Catalyst Pharmaceuticals Inc 98.12%$ 98.116 millions
Biocorrx Inc 97.10%$ 97.105 millions
Cvrx inc 95.76%$ 95.756 millions
Biorestorative Therapies Inc 95.63%$ 95.625 millions
Dyadic International Inc 95.61%$ 95.610 millions
Rxsight Inc 95.58%$ 95.583 millions
Adma Biologics Inc 95.56%$ 95.558 millions
Revance Therapeutics Inc 95.29%$ 95.285 millions
Capforce Inc 94.46%$ 94.455 millions
Evoke Pharma Inc 93.70%$ 93.701 millions
Y mabs Therapeutics inc 93.12%$ 93.124 millions
Omega Therapeutics Inc 92.54%$ 92.537 millions
Hims and Hers Health Inc 88.30%$ 88.296 millions
Prothena Corporation Public Limited Company88.12%$ 88.118 millions
G1 Therapeutics Inc 87.57%$ 87.569 millions
Inspire Medical Systems inc 84.34%$ 84.337 millions
Omniab Inc 75.82%$ 75.818 millions
Hyperfine Inc 74.62%$ 74.619 millions
Aclaris Therapeutics Inc 73.98%$ 73.985 millions
Agilon Health Inc 73.87%$ 73.870 millions
Shockwave Medical Inc 72.02%$ 72.022 millions
Procept Biorobotics Corporation71.90%$ 71.895 millions
Stoke Therapeutics Inc 71.73%$ 71.733 millions
Nephros Inc 71.24%$ 71.237 millions
Akili Inc 71.21%$ 71.212 millions


About Novan Inc Revenue Growth Rates (NOVN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Novan Inc (CIK 1467154).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001467154-23-000047
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Novan Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.